Adjuvant therapy for pancreas cancer in an era of value based cancer care

Daniel Ahn, Terence M. Williams, Daniel A. Goldstein, Bassel El-Rayes, Tanios Bekaii-Saab

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

In resected pancreas cancer, adjuvant therapy improves outcomes and is considered the standard of care for patients who recover sufficiently post operatively. Chemotherapy or combined chemotherapy and radiation therapy (chemoradiation; CRT) are strategies used in the adjuvant setting. However, there is a lack of evidence to suggest whether the addition of RT to chemotherapy translates to an improvement in clinical outcomes. This is true even when accounting for the subset of patients with a higher risk for recurrence, such as those with R1 and lymph node positive disease. When considering the direct and indirect costs, impact on quality of life and questionable added clinical benefit, the true "net health benefit" from added RT to chemotherapy becomes more uncertain. Future directions, including the utilization of modern RT, integration of novel therapies, and intensifying chemotherapy regimens may improve outcomes in resected pancreas cancer.

Original languageEnglish (US)
Pages (from-to)10-17
Number of pages8
JournalCancer Treatment Reviews
Volume42
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Drug Therapy
Neoplasms
Therapeutics
Insurance Benefits
Standard of Care
Radiotherapy
Lymph Nodes
Quality of Life
Costs and Cost Analysis
Recurrence

Keywords

  • Adjuvant therapy
  • Chemoradiation
  • Chemotherapy
  • Net health benefit
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Adjuvant therapy for pancreas cancer in an era of value based cancer care. / Ahn, Daniel; Williams, Terence M.; Goldstein, Daniel A.; El-Rayes, Bassel; Bekaii-Saab, Tanios.

In: Cancer Treatment Reviews, Vol. 42, 01.01.2016, p. 10-17.

Research output: Contribution to journalReview article

Ahn, Daniel ; Williams, Terence M. ; Goldstein, Daniel A. ; El-Rayes, Bassel ; Bekaii-Saab, Tanios. / Adjuvant therapy for pancreas cancer in an era of value based cancer care. In: Cancer Treatment Reviews. 2016 ; Vol. 42. pp. 10-17.
@article{2ff108798c7d41fcbb471748d42e9c4d,
title = "Adjuvant therapy for pancreas cancer in an era of value based cancer care",
abstract = "In resected pancreas cancer, adjuvant therapy improves outcomes and is considered the standard of care for patients who recover sufficiently post operatively. Chemotherapy or combined chemotherapy and radiation therapy (chemoradiation; CRT) are strategies used in the adjuvant setting. However, there is a lack of evidence to suggest whether the addition of RT to chemotherapy translates to an improvement in clinical outcomes. This is true even when accounting for the subset of patients with a higher risk for recurrence, such as those with R1 and lymph node positive disease. When considering the direct and indirect costs, impact on quality of life and questionable added clinical benefit, the true {"}net health benefit{"} from added RT to chemotherapy becomes more uncertain. Future directions, including the utilization of modern RT, integration of novel therapies, and intensifying chemotherapy regimens may improve outcomes in resected pancreas cancer.",
keywords = "Adjuvant therapy, Chemoradiation, Chemotherapy, Net health benefit, Pancreatic cancer",
author = "Daniel Ahn and Williams, {Terence M.} and Goldstein, {Daniel A.} and Bassel El-Rayes and Tanios Bekaii-Saab",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ctrv.2015.11.004",
language = "English (US)",
volume = "42",
pages = "10--17",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Adjuvant therapy for pancreas cancer in an era of value based cancer care

AU - Ahn, Daniel

AU - Williams, Terence M.

AU - Goldstein, Daniel A.

AU - El-Rayes, Bassel

AU - Bekaii-Saab, Tanios

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In resected pancreas cancer, adjuvant therapy improves outcomes and is considered the standard of care for patients who recover sufficiently post operatively. Chemotherapy or combined chemotherapy and radiation therapy (chemoradiation; CRT) are strategies used in the adjuvant setting. However, there is a lack of evidence to suggest whether the addition of RT to chemotherapy translates to an improvement in clinical outcomes. This is true even when accounting for the subset of patients with a higher risk for recurrence, such as those with R1 and lymph node positive disease. When considering the direct and indirect costs, impact on quality of life and questionable added clinical benefit, the true "net health benefit" from added RT to chemotherapy becomes more uncertain. Future directions, including the utilization of modern RT, integration of novel therapies, and intensifying chemotherapy regimens may improve outcomes in resected pancreas cancer.

AB - In resected pancreas cancer, adjuvant therapy improves outcomes and is considered the standard of care for patients who recover sufficiently post operatively. Chemotherapy or combined chemotherapy and radiation therapy (chemoradiation; CRT) are strategies used in the adjuvant setting. However, there is a lack of evidence to suggest whether the addition of RT to chemotherapy translates to an improvement in clinical outcomes. This is true even when accounting for the subset of patients with a higher risk for recurrence, such as those with R1 and lymph node positive disease. When considering the direct and indirect costs, impact on quality of life and questionable added clinical benefit, the true "net health benefit" from added RT to chemotherapy becomes more uncertain. Future directions, including the utilization of modern RT, integration of novel therapies, and intensifying chemotherapy regimens may improve outcomes in resected pancreas cancer.

KW - Adjuvant therapy

KW - Chemoradiation

KW - Chemotherapy

KW - Net health benefit

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84955074329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955074329&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2015.11.004

DO - 10.1016/j.ctrv.2015.11.004

M3 - Review article

VL - 42

SP - 10

EP - 17

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -